journal
MENU ▼
Read by QxMD icon Read
search

RMD Open

journal
https://www.readbyqxmd.com/read/28326189/sarilumab-improves-patient-reported-outcomes-in-rheumatoid-arthritis-patients-with-inadequate-response-intolerance-to-tumour-necrosis-factor-inhibitors
#1
Vibeke Strand, Matthew Reaney, Chieh-I Chen, Clare W J Proudfoot, Sophie Guillonneau, Deborah Bauer, Erin Mangan, Neil M H Graham, Hubert van Hoogstraten, Yong Lin, César Pacheco-Tena, Roy Fleischmann
OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitors (TNF-IR). METHODS: 546 patients (81.9% female, mean age 52.9 years) were randomised to placebo, sarilumab 150 or 200 mg subcutaneously every 2 weeks + csDMARDs...
2017: RMD Open
https://www.readbyqxmd.com/read/28326188/physical-workload-is-associated-with-increased-risk-of-rheumatoid-arthritis-results-from-a-swedish-population-based-case-control-study
#2
Pingling Zeng, Lars Klareskog, Lars Alfredsson, Camilla Bengtsson
OBJECTIVES: This study investigated: (1) the association of physical workload (PW) and risk of rheumatoid arthritis (RA); (2) the potential interactions between PW and the genes in the human leucocyte antigen (HLA) region. METHODS: A population-based case-control study involving incident cases of RA (3150 cases and 5130 controls) was performed using data from the Swedish Epidemiological Investigation of Rheumatoid Arthritis. Information on 7 types of self-reported PW exposure and HLA-DRB1 genotypes of cases and controls were gathered...
2017: RMD Open
https://www.readbyqxmd.com/read/28270934/correction-drug-specific-risk-and-characteristics-of-lupus-and-vasculitis-like-events-in-patients-with-rheumatoid-arthritis-treated-with-tnfi-results-from-bsrbr-ra
#3
(no author information available yet)
[This corrects the article DOI: 10.1136/rmdopen-2016-000314.].
2017: RMD Open
https://www.readbyqxmd.com/read/28270933/no-impact-of-concomitant-methotrexate-use-on-serious-adverse-event-and-serious-infection-risk-in-patients-with-rheumatoid-arthritis-treated-with-bdmards-a-systematic-literature-review-and-meta-analysis
#4
Claire Baradat, Yannick Degboé, Arnaud Constantin, Alain Cantagrel, Adeline Ruyssen-Witrand
OBJECTIVES: To compare the risk of serious adverse events, serious infections and death caused by methotrexate and biological disease-modifying antirheumatic drug (bDMARD) combination therapy versus a bDMARD prescribed as monotherapy in rheumatoid arthritis (RA). METHODS: A systematic literature review was conducted until February 2016 in PubMed, Embase and Cochrane Library databases by selecting randomised controlled trials comparing methotrexate and bDMARD combination therapy to bDMARD monotherapy in RA...
2017: RMD Open
https://www.readbyqxmd.com/read/28255449/das28-crp-and-das28-esr-cut-offs-for-high-disease-activity-in-rheumatoid-arthritis-are-not-interchangeable
#5
Roy M Fleischmann, Désirée van der Heijde, Philip V Gardiner, Annette Szumski, Lisa Marshall, Eustratios Bananis
BACKGROUND: In most patients with rheumatoid arthritis (RA), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) is lower than DAS28 erythrocyte sedimentation rate (DAS28-ESR), suggesting that use of the DAS28-ESR cut-off to assess high disease activity (HDA) with DAS28-CRP may underestimate the number of patients with HDA. We determined the DAS28-CRP value corresponding to the validated DAS28-ESR cut-off for HDA. METHODS: Baseline data were pooled from 2 clinical studies evaluating etanercept (ETN) plus methotrexate (MTX) or MTX in early RA; DAS28-CRP and DAS28-ESR were obtained, allowing the determination of the DAS28-CRP HDA value best corresponding to the DAS28-ESR cut-off of >5...
2017: RMD Open
https://www.readbyqxmd.com/read/28243468/baseline-autoantibodies-preferentially-impact-abatacept-efficacy-in-patients-with-rheumatoid-arthritis-who-are-biologic-na%C3%A3-ve-6-month-results-from-a-real-world-international-prospective-study
#6
Rieke Alten, Hubert G Nüßlein, Xavier Mariette, Mauro Galeazzi, Hanns-Martin Lorenz, Alain Cantagrel, Melanie Chartier, Coralie Poncet, Christiane Rauch, Manuela Le Bars
OBJECTIVES: To determine the impact of baseline rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP) status on the clinical efficacy of intravenous abatacept in biologic-naïve patients with rheumatoid arthritis (RA) enrolled in the real-world ACTION study. METHODS: Clinical outcomes (European League Against Rheumatism (EULAR) response, mean Clinical Disease Activity Index (CDAI) and Boolean remission) at 6 months were compared by baseline RF and anti-CCP status...
2017: RMD Open
https://www.readbyqxmd.com/read/28243467/coronary-heart-disease-is-associated-with-a-worse-clinical-outcome-of-hand-osteoarthritis-a-cross-sectional-and-longitudinal-study
#7
Alice Courties, Jérémie Sellam, Emmanuel Maheu, Christian Cadet, Yoann Barthe, Fabrice Carrat, Francis Berenbaum
OBJECTIVE: To determine whether cardiometabolic factors are associated with hand osteoarthritis (HOA) symptoms, radiographic severity and progression in a post hoc analysis of the phase III Strontium ranelate Efficacy in Knee OsteoarthrItis triAl (SEKOIA) trial, designed to determine the effect of strontium ranelate on knee osteoarthritis (OA). METHODS: Among the 1683 patients randomised in the SEKOIA study, 869 with radiographic HOA at baseline (rHOA≥2 joints with Kellgren-Lawrence grade ≥2) were included in a cross-sectional analysis...
2017: RMD Open
https://www.readbyqxmd.com/read/28243466/update-on-interleukin-17-a-role-in-the-pathogenesis-of-inflammatory-arthritis-and-implication-for-clinical-practice
#8
REVIEW
Pierre Miossec
Interleukin-17 (IL-17A) is a cytokine critical for the acute defence against extracellular bacterial and fungal infections. Excess production during chronic inflammation has been associated with many inflammatory and autoimmune disorders. The present review describes the key molecules of the IL-17 pathway, which are or could be targeted for treatment. Since targeting of IL-17A may affect defence mechanisms, the pathogenesis of such possible adverse events is analysed. Then the contributions of IL-17 to bone changes in various forms of arthritis are discussed...
2017: RMD Open
https://www.readbyqxmd.com/read/28176966/efficacy-and-safety-of-non-pharmacological-and-non-biological-pharmacological-treatment-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#9
COMMENT
Andrea Regel, Alexandre Sepriano, Xenofon Baraliakos, Désirée van der Heijde, Jürgen Braun, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic literature review (2009-2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies was performed. Randomised controlled trials (RCTs) and clinical controlled trials were assessed for efficacy and safety, while observational studies with a comparator were assessed for safety...
2017: RMD Open
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#10
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28155923/diagnosis-prognosis-and-classification-of-early-arthritis-results-of-a-systematic-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-early-arthritis
#11
COMMENT
Charlotte Hua, Claire I Daien, Bernard Combe, Robert Landewe
OBJECTIVE: To update the evidence pertaining to the diagnosis, prognosis and classification of patients with early arthritis (EA), and to inform the 2016 European League Against Rheumatism (EULAR) recommendations for the management of patients with EA. METHODS: MEDLINE, EMBASE and Cochrane databases were searched up to October 2015. The first part of the systematic literature review (SLR) involved a search for studies investigating the recognition and referral of EA...
2017: RMD Open
https://www.readbyqxmd.com/read/28151539/non-pharmacological-and-pharmacological-interventions-in-patients-with-early-arthritis-a-systematic-literature-review-informing-the-2016-update-of-eular-recommendations-for-the-management-of-early-arthritis
#12
Claire Immediato Daien, Charlotte Hua, Bernard Combe, Robert Landewe
OBJECTIVE: To perform a systematic literature review (SLR) on pharmacological and non-pharmacological treatments, in order to inform the European League Against Rheumatism (EULAR) recommendations for the management of early arthritis (EA). METHODS: The expert committee defined research questions concerning non-pharmacological interventions, patient information and education, non-steroidal anti-inflammatory drug, glucocorticoid (GC) and disease-modifying antirheumatic drugs (DMARDs) use, as well as on disease monitoring...
2017: RMD Open
https://www.readbyqxmd.com/read/28123783/persistence-of-low-disease-activity-after-tumour-necrosis-factor-inhibitor-tnfi-discontinuation-in-patients-with-psoriatic-arthritis
#13
D H Huynh, T A Boyd, C J Etzel, V Cox, J Kremer, P Mease, A Kavanaugh
OBJECTIVE: To determine the duration of clinical benefit among patients with psoriatic arthritis (PsA) discontinuing tumour necrosis factor inhibitor (TNFi) therapy while in low disease activity (LDA), and to identify patient characteristics associated with prolonged clinical benefit. METHODS: We performed an observational cohort study assessing patients with PsA from the Consortium of Rheumatology Researchers of North America (CORRONA) registry who had discontinued TNFi after achieving LDA, defined as clinical disease activity index (CDAI) score ≤10 and physician's global assessment (PGA) of skin psoriasis ≤20/100...
2017: RMD Open
https://www.readbyqxmd.com/read/28123782/systematic-review-and-network-meta-analysis-of-the-efficacy-and-safety-of-tumour-necrosis-factor-inhibitor-methotrexate-combination-therapy-versus-triple-therapy-in-rheumatoid-arthritis
#14
Roy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, Derek H Tang, James Chung, David Collier, Shilpa Urs, Kerigo Ndirangu, George Wells, Janet Pope
OBJECTIVE: Clinical trials have not consistently demonstrated differences between tumour necrosis factor inhibitor (TNFi) plus methotrexate and triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in rheumatoid arthritis (RA). The study objective was to estimate the efficacy, radiographic benefits, safety and patient-reported outcomes of TNFi-methotrexate versus triple therapy in patients with RA. METHODS: A systematic review and network meta-analysis (NMA) of randomised controlled trials of TNFi-methotrexate or triple therapy as one of the treatment arms in patients with an inadequate response to or who were naive to methotrexate was conducted...
2017: RMD Open
https://www.readbyqxmd.com/read/28123781/association-of-erythrocyte-methotrexate-polyglutamate-levels-with-the-efficacy-and-hepatotoxicity-of-methotrexate-in-patients-with-rheumatoid-arthritis-a-76-week-prospective-study
#15
Chihiro Takahashi, Yuko Kaneko, Yutaka Okano, Hiroaki Taguchi, Hisaji Oshima, Keisuke Izumi, Kunihiro Yamaoka, Tsutomu Takeuchi
OBJECTIVE: To assess the utility of erythrocyte methotrexate-polyglutamate (MTX-PG) concentrations in determining the safety and efficacy of MTX in patients with rheumatoid arthritis (RA). METHODS: 79 MTX-naïve patients with RA were enrolled in this prospective 76-week cohort study. MTX was initiated, and a predefined dose-escalation protocol was followed. Erythrocyte MTX-PG concentrations were measured using liquid chromatography. The associations of MTX-PG concentrations with disease activity and adverse events were analysed...
2017: RMD Open
https://www.readbyqxmd.com/read/28123780/preliminary-validation-of-the-knee-inflammation-mri-scoring-system-kimriss-for-grading-bone-marrow-lesions-in-osteoarthritis-of-the-knee-data-from-the-osteoarthritis-initiative
#16
Jacob L Jaremko, Dean Jeffery, M Buller, Stephanie Wichuk, Dave McDougall, Robert Gw Lambert, Walter P Maksymowych
OBJECTIVE: Bone marrow lesions (BML) are an MRI feature of osteoarthritis (OA) offering a potential target for therapy. We developed the Knee Inflammation MRI Scoring System (KIMRISS) to semiquantitatively score BML with high sensitivity to small changes, and compared feasibility, reliability and responsiveness versus the established MRI Osteoarthritis Knee Score (MOAKS). METHODS: KIMRISS incorporates a web-based graphic overlay to facilitate detailed regional BML scoring...
2017: RMD Open
https://www.readbyqxmd.com/read/28123779/multireader-assessment-as-an-alternative-to-reference-assessment-to-improve-the-detection-of-radiographic-progression-in-a-large-longitudinal-cohort-of-rheumatoid-arthritis-espoir
#17
Frederique Gandjbakhch, Benjamin Granger, Romain Freund, Violaine Foltz, Sandrine Jousse-Joulin, Valerie Devauchelle, Mona Afshar, Jean David Albert, Florian Bailly, Elodie Constant, Lisa Biale, Morgane Milin, Marion Couderc, Delphine Denarie, Anne Fradin, Virginie Martaille, Audrey Pierreisnard, Nicolas Poursac, Alain Saraux, Bruno Fautrel
INTRODUCTION: Structural damage progression is a major outcome in rheumatoid arthritis (RA). Its evaluation and follow-up in trials should involve radiographic scoring by 1 or 2 readers (reference assessment), which is challenging in large longitudinal cohorts with multiple assessments. OBJECTIVES: To compare the reproducibility of multireader and reference assessment to improve the feasibility of detecting radiographic progression in a large cohort of patients with early arthritis (ESPOIR)...
2017: RMD Open
https://www.readbyqxmd.com/read/28123778/factors-influencing-the-use-of-tocilizumab-as-monotherapy-in-patients-with-rheumatoid-arthritis-in-a-real-life-setting-results-at-1%C3%A2-year-of-the-act-solo-study
#18
René-Marc Flipo, Jean-Francis Maillefert, Pascal Chazerain, Isabelle Idier, Mathieu Coudert, Jacques Tebib
INTRODUCTION: Using a biologic disease-modifying antirheumatic drug (bDMARD) as monotherapy in clinical practice for patients with rheumatoid arthritis (RA) is common and recognised by health authorities although current guidelines recommend to combine them with conventional synthetic (cs)DMARDs. This study mainly aimed to search for real-life factors influencing the use of tocilizumab as MONO or in combination (COMBO). METHODS: In this non-interventional, prospective, national, multicentre study, data were collected every 3 months over a 12-month period in RA patients starting tocilizumab...
2017: RMD Open
https://www.readbyqxmd.com/read/28123777/serum-inflammatory-biomarkers-fail-to-identify-early-axial-spondyloarthritis-results-from-the-spondyloarthritis-caught-early-space-cohort
#19
Maureen C Turina, Nataliya Yeremenko, Floris van Gaalen, Maikel van Oosterhout, Inger J Berg, Ramona Ramonda, Cristina M C Lebre, Robert Landewé, Dominique Baeten
INTRODUCTION: Decreasing the diagnostic delay in axial spondyloarthritis (axSpA) remains a major challenge. Here, we assessed the value of serum inflammatory biomarkers to distinguish early axSpA from other pathologies in a large cohort of patients referred with early back pain. METHODS: Serum c reactive protein (CRP), erythrocyte sedimentation rate (ESR) and calprotectin were determined in the SPondyloArthritis Caught Early (SPACE) cohort (n=310), an early back pain inception cohort...
2017: RMD Open
https://www.readbyqxmd.com/read/28123776/drug-specific-risk-and-characteristics-of-lupus-and-vasculitis-like-events-in-patients-with-rheumatoid-arthritis-treated-with-tnfi-results-from-bsrbr-ra
#20
Meghna Jani, William G Dixon, Lianne Kersley-Fleet, Ian N Bruce, Hector Chinoy, Anne Barton, Mark Lunt, Kath Watson, Deborah P Symmons, Kimme L Hyrich
OBJECTIVE: To compare the risk of lupus-like events (LLEs) and vasculitis-like events (VLEs) in tumour necrosis factor-α inhibitor (TNFi)-treated patients with rheumatoid arthritis (RA) to those receiving non-biological disease-modifying antirheumatic drugs (nbDMARDs). METHODS: Patients were recruited to the British Society for Rheumatology Biologics Register-RA, a national prospective cohort study. Two cohorts recruited between 2001 and 2015: (1) patients starting first TNFi (adalimumab, etanercept, infliximab and certolizumab) (n=12 937) and (2) biological-naïve comparison cohort receiving nbDMARDs (n=3673)...
2017: RMD Open
journal
journal
52478
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"